Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 45

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 45
---
 preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.                       |

| Q: | Who should I contact if I have further questions? |

| A: | For any further questions in connection with any of the matters set out in this Circular and Proxy Statement,                                                         
 please contact the Chief Financial Officer of the Company 7171 Frederick-Banting, Building 2, Suite 270, St. Laurent, Québec, Canada or by phone at 1 (857) 412-7018. |

23

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING INFORMATION

This Circular and Proxy Statement, and any related oral statements made or to be made by us or on our behalf, contains certain
information which, as presented, constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian
Securities Laws (collectively, “forward-looking statements”). Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial
performance, containing words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” and “intend,” statements that an action or event “may,”
“might,” “could,” “should,” or “will” be taken or occur, or other similar expressions and include, but are not limited to, statements: regarding the Arrangement; anticipated timing for holding the
Special Meeting; the intentions, plans and future actions of the Purchaser and the Company; potential benefits, risks and effects of the Arrangement; our ability to consummate the Arrangement on the anticipated terms of the Agreement, if at all; the
likelihood of the Arrangement being completed; the proposed timing and completion of the Arrangement; statements made in, and based upon, the opinion of Leerink Partners; the timing and receipt of necessary approvals including Court, Securityholder,
stock exchange, regulatory and other third-party approvals; de-listing from Nasdaq and de-registering from the Exchange Act; the amounts payable under the Arrangement
and pursuant to the CVRs; the Company’s plans or ability to enter into, or complete, any potential transactions to license or dispose of its product candidates and/or intellectual property related to its
(i) RP-3467 and Polq program, (ii) RP-1664